Stay updated with breaking news from Action Date. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
US FDA accepted NDA filing for ensifentrine for maintenance treatment of COPD PDUFA Target Action Date of June 26, 2024 Commercial launch preparations supported by strong balance sheet Conference...
PDUFA Target Action Date of June 26, 2024 Pooled analysis and subgroup data further support potential of ensifentrine, an investigational, novel, selective, dual inhibitor of PDE3 and PDE4 LONDON...
Label Expansion Decisions Expected from U.S. and European Regulatory Authorities in Q4 SAN RAFAEL, Calif., Sept. 21, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. , a global biotechnology...
BioMarin Pharmaceutical Inc. announced that new data on VOXZOGO®? in children with achondroplasia will be presented at the 61st Annual European Society for Paediatric Endocrinology Meeting in The...
(RTTNews) - BioMarin Pharmaceutical Inc. (BMRN) announced the European Medicines Agency's Committee for Medicinal Products for Human Use has adopt...